Skip to main content

USO DE APROXIMACIONES DE CELULA UNICA PARA DECIFRAR LA EPIGENOMICA DEL CANCER Y LAS EPIDROGAS

PID2021-125282OB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2021
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

  • Martinez-Verbo, Laura
  • Veselinova, Yoana|||0000-0003-4124-9788
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Noguera Castells, Aleix|||0000-0001-7436-6513
  • Pato, Miguel L.|||0000-0001-8840-7259
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Villanueva, Lorea|||0000-0003-1858-7076
  • Oliver-Caldés, Aina|||0000-0002-7921-5420
  • Cardus, Oriol|||0000-0002-5446-5423
  • Salsench, Sergi V.|||0000-0002-4390-6887
  • García-Ortiz, Almudena
  • Valeri, Antonio
  • Rojas, Elizabeta A.
  • Barrena, Naroa|||0000-0003-4324-3371
  • Gutiérrez, Norma C.
  • Prósper, Felipe
  • Agirre, Xabier|||0000-0002-6558-9560
  • Fernández de Larrea, Carlos|||0000-0003-4930-9255
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Esteller, M|||0000-0003-4490-6093
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity

  • Sibai, Mustafa
  • Cervilla, Sergi
  • Grases, Daniela
  • Musulen, Eva
  • Lazcano, Rossana
  • Mo, Chia-Kuei
  • Davalos, Veronica
  • Fortian, Arola
  • Bernat, Adrià
  • Romeo, Margarita
  • Tokheim, Collin
  • Barretina, Jordi
  • Lazar, Alexander J.
  • Ding, Li
  • DUTRENEO Study Investigators
  • Grande, Enrique
  • Real, Francisco X.
  • Esteller, Manel
  • Bailey, Matthew H.
  • Porta-Pardo, Eduard
Tumors are complex ecosystems of interacting cell types. The concept of cancer hallmarks distills this complexity into underlying principles that govern tumor growth. Here, we explore the spatial distribution of cancer hallmarks across 63 primary untreated tumors from 10 cancer types using spatial transcriptomics. We show that hallmark activity is spatially organized, with the cancer compartment contributing to the activity of seven out of 13 hallmarks, while the tumor microenvironment (TME) contributes to the activity of the rest. Additionally, we discover that genomic distance between tumor subclones correlates with differences in hallmark activity, even leading to clone-hallmark specialization. Finally, we demonstrate interdependent relationships between hallmarks at the junctions of TME and cancer compartments and how they relate to sensitivity to different neoadjuvant treatments in 33 bladder cancer patients from the DUTRENEO trial. In conclusion, our findings may improve our understanding of tumor ecology and help identify new drug biomarkers., This research was funded by MCIN/AEI/10.13039/501100011033 and the ERDF through PID2021-125282OB-I00, Generalitat de Catalunya (2021 SGR 01494) and the Sarah Jennifer Knott Foundation. The authors would like to thank Abel Gonzalez-Perez, Nuria Lopez-Bigas, and Eliezer Van Allen for their valuable feedback and the kind and generous patients who donated the samples that made this study possible. This work has been done as part of the PhD Programme in "Biochemistry, molecular biology and biomedicine" from Universitat Autonoma de Barcelona.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A technical comparison of spatial transcriptomics platforms across six cancer types

  • Cervilla, Sergi
  • Grases, Daniela
  • Pérez, Elena
  • Real, Francisco X.
  • Musulen, Eva
  • Aprea, Julieta
  • Esteller, Manel
  • Porta-Pardo, Eduard
Background: Spatial transcriptomics (ST) technologies are reshaping our understanding of tissue organization and cellular context in health and disease. However, technical benchmarking across platforms remains limited, particularly in formalin-fixed, paraffin-embedded (FFPE) clinical samples, which represent the most common tissue format in oncology. Results: Here, we systematically benchmark five commercial ST platforms (Visium v1, Visium v2/CytAssist, Visium HD, Xenium, and CosMx) using matched FFPE human tumor sections from six cancer types. Uniquely, our study includes both sequencing-based and imaging-based platforms profiled on the same samples, enabling direct technical comparisons across spatial capture modalities. We evaluate platform performance across multiple dimensions, including transcript and UMI detection, gene-histology concordance, cell type recovery, and integration with a targeted protein panel (Visium v2, 30 proteins), enabling spatial multi-omics. We also quantify the impact of sampling strategies and area coverage on cell type estimation, revealing trade-offs in spatial resolution versus tissue context. Notably, we present the first same-sample comparison of Xenium Multi-Tissue (377 genes) and Xenium Prime (5,000 genes), highlighting key differences in transcript recovery and spatial signal despite shared chemistry and imaging infrastructure. Finally, we integrate Visium targeted protein data with matched RNA profiles, uncovering widespread RNA-protein decoupling and spatial heterogeneity in concordance. Conclusions: Collectively, this work provides a harmonized dataset and technical reference for the spatial transcriptomics community, offering insight into the relative strengths, limitations, and design considerations associated with high-throughput spatial profiling of FFPE tumors., This work was supported by Nanostring and Longwood Laboratories (who funded the CosMx experiments), 10x Genomics and Bonsai Labs (who funded the Xenium experiments), and Asociación Española Contra el Cáncer (who funded the VISIUM experiments, LABAE20038PORT). S.C is supported by AECC (LABAE20038PORT). E.P-P is supported by the Spanish Ministry of Science (RYC2019-026415-I), a Fundación FERO fellowship (BFERO2022.6), grant PID2024-159258OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01309). S.C. is supported by the FI-STEP predoctoral grants program of the Department of Research and Universities of the Government of Catalonia (Generalitat de Catalunya), and co-financing by the European Social Fund Plus (2025 STEP 00466) ME is supported by MCIN/AEI/10.13039/501100011033 /and the European Regional Development Fund, ‘A way to make Europe’ ERDF (project PID2021-125282OB-I00); Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01494), European Union under THRIVE Grant Agreement Nr. 101136622 and Fundación Científica de la Asociación Contra el Cáncer (ASPIRE project, RETOS245779LLOV).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The multiomics blueprint of the individual with the most extreme lifespan

  • Santos-Pujol, Eloy
  • Noguera-Castells, Aleix
  • Casado-Pelaez, Marta
  • García-Prieto, Carlos A
  • Vasallo, Claudia
  • Campillo-Marcos, Ignacio
  • Quero-Dotor, Carlos
  • Crespo-García, Eva
  • Bueno-Costa, Alberto
  • Setién, Fernando
  • Ferrer, Gerardo
  • Davalos, Veronica
  • Mereu, Elisabetta
  • Pluvinet, Raquel
  • Arribas, Carles
  • Torre, Carolina de la
  • Villavicencio, Francisco
  • Sumoy, Lauro
  • Granada, Isabel
  • Coles, Natalie S
  • Acha, Pamela
  • Solé, Francesc
  • Mallo, Mar
  • Mata, Caterina
  • Peregrina, Sara
  • Gabaldón, Toni
  • Llirós, Marc
  • Pujolassos, Meritxell
  • Carreras-Torres, Robert
  • Lluansí, Aleix
  • García-Gil, Librado Jesús
  • Aldeguer, Xavier
  • Samino, Sara
  • Torné, Pol
  • Ribalta, Josep
  • Guardiola, Montse
  • Amigó, Núria
  • Yanes, Oscar
  • Martínez, Paula
  • Sánchez-Vázquez, Raúl
  • Blasco, Maria A
  • Oviedo, Jose
  • Lemos, Bernardo
  • Rius-Bonet, Julia
  • Torrubiano, Marta
  • Massip-Salcedo, Marta
  • Khidir, Kamal A
  • Cao, Thong Huy
  • Quinn, Paulene A
  • Jones, Donald J L
  • Macip, Salvador
  • Brigos-Barril, Eva
  • Moldes, Mauricio
  • Barteri, Fabio
  • Muntané, Gerard
  • Laayouni, Hafid
  • Navarro, Arcadi
  • Esteller, Manel
Extreme human lifespan, exemplified by supercentenarians, presents a paradox in understanding aging: despite advanced age, they maintain relatively good health. To investigate this duality, we have performed a high-throughput multiomics study of the world's oldest living person, interrogating her genome, transcriptome, metabolome, proteome, microbiome, and epigenome, comparing the results with larger matched cohorts. The emerging picture highlights different pathways attributed to each process: the record-breaking advanced age is manifested by telomere attrition, abnormal B cell population, and clonal hematopoiesis, whereas absence of typical age-associated diseases is associated with rare European-population genetic variants, low inflammation levels, a rejuvenated bacteriome, and a younger epigenome. These findings provide a fresh look at human aging biology, suggesting biomarkers for healthy aging, and potential strategies to increase life expectancy. The extrapolation of our results to the general population will require larger cohorts and longitudinal prospective studies to design potential anti-aging interventions., We thank Yoana Veselinova for the drawing of the graphical abstract. Research in the M.E. group is funded by the CERCA Programme/Generalitat de Catalunya (MCIN/AEI/10.13039/501100011033/); the European Regional Development Fund, “A way to make Europe” ERDF (project PID2021-125282OB-I00 and PID2024-159192OB-I00); Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01494); European Union under THRIVE grant agreement no. 101136622; “La Caixa” Research Foundation; and the Cellex Foundation (CEL007). E.S.-P. is a fellow of the Spanish Ministry of Science, Innovation and Universities, under FPI contract no. PRE2022-105015. G.F. is a recipient of Ayuda Investigador AECC 2023 (INVES234765FERR), Fundación Científica AECC. C.Q.-D. is a fellow of the Spanish Ministry of Science, Innovation and Universities, under FPU contract no. FPU22/01655. E.M.’s work in this publication was supported by the Ramón y Cajal fellowship RYC2021-032359-I, funded by the Spanish Ministry of Science and the Catalan Agency for Management of University and Research Grants (AGAUR, 2021 SGR 01586). Research in the A.N. group is supported by the I+D+i project PID2021-127792NB-I00, funded by MCIN/AEI/10.13039/501100011033 (FEDER Una manera de hacer Europa), and “Unidad de Excelencia María de Maeztu,” funded by the AEI (CEX2018-000792-M) and Departament de Recerca i Universitats de la Generalitat de Catalunya (GRC 2021 SGR 0467). Research in the R.C.-T.. group is funded by the Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01366). Research in the S.M. group was supported by the Instituto de Salud Carlos III (PI20/00328) and the M. C. Andreu Memorial Fund. J.R.-B. was supported by a doctoral grant from the Universitat Oberta de Catalunya. Research in the M.A.B. laboratory is funded by the European Union, project ERC-AvG Shelterins (GA 882385), Horizon 2020 Programme. The mass spectrometry work was supported by the John and Lucille Van Geest Foundation and the National Institute for Health and Care Research Leicester Biomedical Research Centre. M.E. is an ICREA Research Professor., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity

  • Sibai, Mustafa
  • Cervilla, Sergi
  • Grases, Daniela
  • Musulen, Eva
  • Lazcano, Rossana
  • Mo, Chia-Kuei
  • Davalos, Veronica
  • Fortian, Arola
  • Bernat, Adrià
  • Romeo, Margarita
  • Tokheim, Collin
  • Barretina, Jordi
  • Lazar, Alexander J.
  • Ding, Li
  • DUTRENEO Study Investigators
  • Grande, Enrique
  • Real, Francisco X.
  • Esteller, Manel
  • Bailey, Matthew H.
  • Porta-Pardo, Eduard
Tumors are complex ecosystems of interacting cell types. The concept of cancer hallmarks distills this complexity into underlying principles that govern tumor growth. Here, we explore the spatial distribution of cancer hallmarks across 63 primary untreated tumors from 10 cancer types using spatial transcriptomics. We show that hallmark activity is spatially organized, with the cancer compartment contributing to the activity of seven out of 13 hallmarks, while the tumor microenvironment (TME) contributes to the activity of the rest. Additionally, we discover that genomic distance between tumor subclones correlates with differences in hallmark activity, even leading to clone-hallmark specialization. Finally, we demonstrate interdependent relationships between hallmarks at the junctions of TME and cancer compartments and how they relate to sensitivity to different neoadjuvant treatments in 33 bladder cancer patients from the DUTRENEO trial. In conclusion, our findings may improve our understanding of tumor ecology and help identify new drug biomarkers., This research was funded by MCIN/AEI/10.13039/501100011033 and the ERDF through PID2021-125282OB-I00, Generalitat de Catalunya (2021 SGR 01494) and the Sarah Jennifer Knott Foundation. The authors would like to thank Abel Gonzalez-Perez, Nuria Lopez-Bigas, and Eliezer Van Allen for their valuable feedback and the kind and generous patients who donated the samples that made this study possible. This work has been done as part of the PhD Programme in "Biochemistry, molecular biology and biomedicine" from Universitat Autonoma de Barcelona.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A technical comparison of spatial transcriptomics platforms across six cancer types

  • Cervilla, Sergi
  • Grases, Daniela
  • Pérez, Elena
  • Real, Francisco X.
  • Musulen, Eva
  • Aprea, Julieta
  • Esteller, Manel
  • Porta-Pardo, Eduard
Background: Spatial transcriptomics (ST) technologies are reshaping our understanding of tissue organization and cellular context in health and disease. However, technical benchmarking across platforms remains limited, particularly in formalin-fixed, paraffin-embedded (FFPE) clinical samples, which represent the most common tissue format in oncology. Results: Here, we systematically benchmark five commercial ST platforms (Visium v1, Visium v2/CytAssist, Visium HD, Xenium, and CosMx) using matched FFPE human tumor sections from six cancer types. Uniquely, our study includes both sequencing-based and imaging-based platforms profiled on the same samples, enabling direct technical comparisons across spatial capture modalities. We evaluate platform performance across multiple dimensions, including transcript and UMI detection, gene-histology concordance, cell type recovery, and integration with a targeted protein panel (Visium v2, 30 proteins), enabling spatial multi-omics. We also quantify the impact of sampling strategies and area coverage on cell type estimation, revealing trade-offs in spatial resolution versus tissue context. Notably, we present the first same-sample comparison of Xenium Multi-Tissue (377 genes) and Xenium Prime (5,000 genes), highlighting key differences in transcript recovery and spatial signal despite shared chemistry and imaging infrastructure. Finally, we integrate Visium targeted protein data with matched RNA profiles, uncovering widespread RNA-protein decoupling and spatial heterogeneity in concordance. Conclusions: Collectively, this work provides a harmonized dataset and technical reference for the spatial transcriptomics community, offering insight into the relative strengths, limitations, and design considerations associated with high-throughput spatial profiling of FFPE tumors., This work was supported by Nanostring and Longwood Laboratories (who funded the CosMx experiments), 10x Genomics and Bonsai Labs (who funded the Xenium experiments), and Asociación Española Contra el Cáncer (who funded the VISIUM experiments, LABAE20038PORT). S.C is supported by AECC (LABAE20038PORT). E.P-P is supported by the Spanish Ministry of Science (RYC2019-026415-I), a Fundación FERO fellowship (BFERO2022.6), grant PID2024-159258OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01309). S.C. is supported by the FI-STEP predoctoral grants program of the Department of Research and Universities of the Government of Catalonia (Generalitat de Catalunya), and co-financing by the European Social Fund Plus (2025 STEP 00466) ME is supported by MCIN/AEI/10.13039/501100011033 /and the European Regional Development Fund, ‘A way to make Europe’ ERDF (project PID2021-125282OB-I00); Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01494), European Union under THRIVE Grant Agreement Nr. 101136622 and Fundación Científica de la Asociación Contra el Cáncer (ASPIRE project, RETOS245779LLOV).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Single-Cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy

  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Casado Pelaez, Marta|||0000-0002-8428-8384
  • Davalos, Veronica|||0000-0003-4077-5137
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Mata, Caterina|||0000-0001-9403-7434
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Roué, Gaël|||0000-0003-0245-2257
  • Valcárcel, David|||0000-0002-8747-078X
  • Molero, Antonieta|||0000-0002-3735-465X
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Acha, Pamela|||0000-0002-4528-1219
  • Manzanares Mileo, Ana|||0000-0003-4125-4675
  • Tobiasson, Magnus|||0000-0002-3633-5852
  • Hellström-Lindberg, Eva|||0000-0002-7839-3743
  • Sole, F|||0000-0002-3251-2161
  • Esteller, M|||0000-0003-4490-6093
Alterations in epigenetic marks, such as DNA methylation, represent a hallmark of cancer that has been successfully exploited for therapy in myeloid malignancies. Hypomethylating agents (HMAs), such as azacitidine (AZA), have become standard-of-care therapy to treat myelodysplastic syndromes (MDS), myeloid neoplasms that can evolve into acute myeloid leukemia (AML). However, our capacity to identify who will respond to HMAs, and the duration of response, remains limited. To shed light on this question, we have leveraged the unprecedented analytical power of single-cell technologies to simultaneously map the genome and immunoproteome of MDS samples throughout clinical evolution. We were able to chart the architecture and evolution of molecular clones in precious paired bone marrow MDS samples at diagnosis and post-treatment to show that a combined imbalance of specific cell lineages with diverse mutational profiles is associated with the clinical response of MDS patients to hypomethylating therapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Validation of the new EPIC DNA methylation microarray (900K EPIC v2) for high-throughput profiling of the human DNA methylome

  • Noguera Castells, Aleix|||0000-0001-7436-6513
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Álvarez-Errico, Damiana|||0000-0002-7921-5164
  • Esteller, M|||0000-0003-4490-6093
DNA methylation, one of the best characterized epigenetic marks in the human genome, plays a pivotal role in gene transcription regulation and other biological processes in humans. On top of that, the DNA methylome undergoes profound changes in cancer and other disorders. However, large-scale and population-based studies are limited by high costs and the need for considerable expertise in data analysis for whole-genome bisulphite-sequencing methodologies. Following the success of the EPIC DNA methylation microarray, the newly developed Infinium HumanMethylationEPIC version 2.0 (900K EPIC v2) is now available. This new array contains more than 900,000 CpG probes covering the human genome and excluding masked probes from the previous version. The 900K EPIC v2 microarray adds more than 200,000 probes covering extra DNA cis-regulatory regions such as enhancers, super-enhancers and CTCF binding regions. Herein, we have technically and biologically validated the new methylation array to show its high reproducibility and consistency among technical replicates and with DNA extracted from FFPE tissue. In addition, we have hybridized primary normal and tumoural tissues and cancer cell lines from different sources and tested the robustness of the 900K EPIC v2 microarray when analysing the different DNA methylation profiles. The validation highlights the improvements offered by the new array and demonstrates the versatility of this updated tool for characterizing the DNA methylome in human health and disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer

  • Ortiz-Barahona, Vanessa
  • Soler, Marta|||0000-0002-6656-957X
  • Davalos, Veronica|||0000-0003-4077-5137
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Janin, Maxime|||0000-0003-1013-4128
  • Setien, Fernando|||0000-0002-4061-4635
  • Fernández-Rebollo, Irene
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • De La Torre, Carolina
  • Guil, Sonia|||0000-0002-2257-3331
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Zhang, Pei Hong
  • Yang, Li
  • Guarnacci, Marco
  • Schumann, Ulrike
  • Preiss, Thomas
  • Balaseviciute, Ugne
  • Montal, Robert
  • Llovet, Josep M.|||0000-0003-0547-2667
  • Esteller, M.|||0000-0003-4490-6093
Background: RNA modifications are important regulators of transcript activity and an increasingly emerging body of data suggests that the epitranscriptome and its associated enzymes are altered in human tumors. Methods: Combining data mining and conventional experimental procedures, NSUN7 methylation and expression status was assessed in liver cancer cell lines and primary tumors. Loss-of-function and transfection-mediated recovery experiments coupled with RNA bisulfite sequencing and proteomics determined the activity of NSUN7 in downstream targets and drug sensitivity. Results: In this study, the initial screening for genetic and epigenetic defects of 5-methylcytosine RNA methyltransferases in transformed cell lines, identified that the NOL1/NOP2/Sun domain family member 7 (NSUN7) undergoes promoter CpG island hypermethylation-associated with transcriptional silencing in a cancer-specific manner. NSUN7 epigenetic inactivation was common in liver malignant cells and we coupled bisulfite conversion of cellular RNA with next-generation sequencing (bsRNA-seq) to find the RNA targets of this poorly characterized putative RNA methyltransferase. Using knock-out and restoration-of-function models, we observed that the mRNA of the coiled-coil domain containing 9B (CCDC9B) gene required NSUN7-mediated methylation for transcript stability. Most importantly, proteomic analyses determined that CCDC9B loss impaired protein levels of its partner, the MYC-regulator Influenza Virus NS1A Binding Protein (IVNS1ABP), creating sensitivity to bromodomain inhibitors in liver cancer cells exhibiting NSUN7 epigenetic silencing. The DNA methylation-associated loss of NSUN7 was also observed in primary liver tumors where it was associated with poor overall survival. Interestingly, NSUN7 unmethylated status was enriched in the immune active subclass of liver tumors. Conclusion: The 5-methylcytosine RNA methyltransferase NSUN7 undergoes epigenetic inactivation in liver cancer that prevents correct mRNA methylation. Furthermore, NSUN7 DNA methylation-associated silencing is associated with clinical outcome and distinct therapeutic vulnerability.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine, A multicentre retrospective study

  • Noguera Castells, Aleix|||0000-0001-7436-6513
  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Davalos, Veronica|||0000-0003-4077-5137
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Valcárcel, David|||0000-0002-8747-078X
  • Molero, Antonieta|||0000-0002-3735-465X
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Gattermann, Norbert
  • Wulfert, Michael
  • Chaparro, Lorea
  • Sole, F.|||0000-0002-3251-2161
  • Cabezón, Marta|||0000-0001-5122-7481
  • Jiménez-Lorenzo, María J.
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Zamora, Lurdes|||0000-0003-1713-7110
  • De Stefano, Alessia
  • Casalin, Irene
  • Finelli, C.
  • Follo, Matilde Y.
  • Esteller, M.|||0000-0003-4490-6093
Real-world data have revealed that a substantial portion of patients with myelodysplastic syndromes (MDS) does not respond to epigenetic therapy with hypomethylating agents (HMAs). The cellular and molecular reasons for this resistance to the demethylating agent and biomarkers that would be able to predict the treatment refractoriness are largely unknown. In this study, we shed light on this enigma by characterizing the epigenomic profiles of patients with MDS treated with azacitidine. Our approach provides a comprehensive view of the evolving DNA methylation architecture of the disease and holds great potential for advancing our understanding of MDS treatment responses to HMAs.